Silence Therapeutics (SLN) Equity Average (2019 - 2025)
Historic Equity Average for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $84.1 million.
- Silence Therapeutics' Equity Average fell 3739.67% to $84.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.1 million, marking a year-over-year decrease of 3739.67%. This contributed to the annual value of $78.0 million for FY2024, which is 21701.55% up from last year.
- Silence Therapeutics' Equity Average amounted to $84.1 million in Q3 2025, which was down 3739.67% from $103.4 million recorded in Q2 2025.
- Silence Therapeutics' Equity Average's 5-year high stood at $149.4 million during Q2 2024, with a 5-year trough of $8.4 million in Q1 2022.
- For the 5-year period, Silence Therapeutics' Equity Average averaged around $68.0 million, with its median value being $56.0 million (2025).
- Per our database at Business Quant, Silence Therapeutics' Equity Average skyrocketed by 74155.98% in 2024 and then crashed by 3739.67% in 2025.
- Quarter analysis of 5 years shows Silence Therapeutics' Equity Average stood at $17.0 million in 2021, then tumbled by 50.52% to $8.4 million in 2022, then surged by 175.97% to $23.2 million in 2023, then skyrocketed by 460.77% to $130.4 million in 2024, then crashed by 35.48% to $84.1 million in 2025.
- Its Equity Average stands at $84.1 million for Q3 2025, versus $103.4 million for Q2 2025 and $123.4 million for Q1 2025.